Monday, August 6, 2012

Spontaneous Trigeminal Allodynia in Rats: A Model of Primary Headache


Headache: The Journal of Head and Face Pain

  1. M.L. Oshinsky PhD*
  2. M.M. Sanghvi MS, 
  3. C.R. Maxwell PhD, 
  4. D. Gonzalez MS, 
  5. R.J. Spangenberg MLAS, 
  6. M. Cooper BS, 
  7. S.D. Silberstein MD
  1.  michael.oshinsky@jefferson.edu
DOI: 10.1111/j.1526-4610.2012.02247.x
    Abstract
Animal models are essential for studying the pathophysiology of headache disorders and as a screening tool for new therapies. Most animal models modify a normal animal in an attempt to mimic migraine symptoms. They require manipulation to activate the trigeminal nerve or dural nociceptors. At best, they are models of secondary headache. No existing model can address the fundamental question: How is a primary headache spontaneously initiated?
In the process of obtaining baseline periorbital von Frey thresholds in a wild-type Sprague-Dawley rat, we discovered a rat with spontaneous episodic trigeminal allodynia (manifested by episodically changing low periorbital pain threshold). Subsequent mating showed that the trait is inherited. Animals with spontaneous trigeminal allodynia allow us to study the pathophysiology of primary recurrent headache disorders.
To validate this as a model for migraine, we tested the effects of clinically proven acute and preventive migraine treatments on spontaneous changes in rat periorbital sensitivity. Sumatriptan, ketorolac, and dihydroergotamine temporarily reversed the low periorbital pain thresholds. Thirty days of chronic valproic acid treatment prevented spontaneous changes in trigeminal allodynia. After discontinuation, the rats returned to their baseline of spontaneous episodic threshold changes. We also tested the effects of known chemical and dietary human migraine triggers. On days when the rats did not have allodynia and showed normal periorbital von Frey thresholds, glycerol trinitrate and calcitonin gene related peptide induced significant decreases in the periorbital pain threshold.
This model can be used as a predictive model for drug development and for studies of putative biomarkers for headache diagnosis and treatment.
© 2012 American Headache Society

No comments:

Post a Comment